专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08465917B2 Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells 有权
标题翻译：确定肝细胞癌亚型和检测肝癌干细胞的方法
公开(公告)号：US08465917B2
公开(公告)日：2013-06-18
申请号：US12663586
申请日：2008-06-09
申请人： Xin Wei Wang , Junfang Ji , Taro Yamashita , Carlo M. Croce
发明人： Xin Wei Wang , Junfang Ji , Taro Yamashita , Carlo M. Croce
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , C12Q2600/178 , G01N33/6893
摘要： The invention provides a method of determining an HCC subtype in a subject comprising a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. The invention further provides methods of detecting HCC stem cells in a sample. Additionally, the invention provides methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells.
摘要翻译：本发明提供了确定受试者中HCC亚型的方法，其包括a）从受试者获得样品，b）测定样品以检测1种或更多种生物标志物的表达，以及c）将生物标志物的表达与HCC相关联受试者的亚型。本发明还提供了检测样品中HCC干细胞的方法。另外，本发明提供用于治疗HCC受试者利用与HCC干细胞相关的生物标志物的方法和组合物。

2. 发明申请

US20100197770A1 Methods for Determining Heptocellular Carcinoma Subtype and Detecting Hepatic Cancer Stem Cells 有权
标题翻译：确定肝细胞癌亚型和检测肝癌干细胞的方法
公开(公告)号：US20100197770A1
公开(公告)日：2010-08-05
申请号：US12663586
申请日：2008-06-09
申请人： Xin Wei Wang , Junfang Ji , Taro Yamashita , Carlo M. Croce
发明人： Xin Wei Wang , Junfang Ji , Taro Yamashita , Carlo M. Croce
IPC分类号： A61K31/7088 , C12Q1/68 , C40B30/04 , C12Q1/02 , G01N33/559
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , C12Q2600/178 , G01N33/6893
摘要： The invention provides a method of determining an HCC subtype in a subject comprising a) obtaining a sample from the subject, b) assaying the sample to detect the expression of 1 or more biomarkers, and c) correlating the expression of the biomarkers with an HCC subtype in a subject. The invention further provides methods of detecting HCC stem cells in a sample. Additionally, the invention provides methods and compositions for treating subjects with HCC that take advantage of the biomarkers associated with HCC stem cells.
摘要翻译：本发明提供了确定受试者中HCC亚型的方法，其包括a）从受试者获得样品，b）测定样品以检测1种或更多种生物标志物的表达，以及c）将生物标志物的表达与HCC相关联受试者的亚型。本发明还提供了检测样品中HCC干细胞的方法。另外，本发明提供用于治疗HCC受试者利用与HCC干细胞相关的生物标志物的方法和组合物。

3. 发明授权

US09125923B2 Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy 有权
标题翻译：使用MiR-26家族作为肝细胞癌的预测指标和对治疗的反应
公开(公告)号：US09125923B2
公开(公告)日：2015-09-08
申请号：US12997419
申请日：2009-06-11
申请人： Xin W. Wang , Junfang Ji , Carlo M. Croce , Hui-chuan Sun , Zhao-you Tang
发明人： Xin W. Wang , Junfang Ji , Carlo M. Croce , Hui-chuan Sun , Zhao-you Tang
IPC分类号： C40B30/04 , A61K31/70 , C12Q1/68
CPC分类号： A61K31/70 , A61K38/212 , C12Q1/6809 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/178 , C12Q2525/207
摘要： It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-α therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-α therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided. Further provided are methods of treating a patient diagnosed with HCC and expressing a low level of miR-26, wherein treatment comprises IFN-α therapy.
摘要翻译：本文公开了相对于非癌组织，肝细胞（HCC）肿瘤组织中microRNA-26的表达降低，并且低水平的microRNA-26与不良临床结果相关。本文还公开了低表达水平的微小RNA-26与HCC患者中对干扰素（IFN）-α治疗的有利反应相关。因此，本文提供了一种预测诊断为HCC的患者的临床结果的方法，包括检测从患者获得的样品中的microRNA-26表达水平。还提供了选择被诊断为HCC的患者作为IFN-α治疗的候选者的方法，包括检测从患者获得的样品中的microRNA-26表达水平。还提供了鉴定用于治疗HCC的治疗剂的方法，其包括在体外筛选候选试剂以选择增加HCC细胞中微小RNA-26表达的试剂。还提供了治疗诊断为HCC并表达低水平的miR-26的患者的方法，其中治疗包括IFN-α治疗。

4. 发明申请

US20110124521A1 Use of MiR-26 Family as a Predictive Marker for Hepatocellular Carcinoma and Responsiveness to Therapy 有权
标题翻译：使用MiR-26家族作为肝细胞癌的预测标记和对治疗的反应
公开(公告)号：US20110124521A1
公开(公告)日：2011-05-26
申请号：US12997419
申请日：2009-06-11
申请人： Xin W. Wang , Junfang Ji , Carlo M. Croce , Hui-Chuan Sun , Zhao-you Tang
发明人： Xin W. Wang , Junfang Ji , Carlo M. Croce , Hui-Chuan Sun , Zhao-you Tang
IPC分类号： C40B30/04
CPC分类号： A61K31/70 , A61K38/212 , C12Q1/6809 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/178 , C12Q2525/207
摘要： It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-α therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-α therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided. Further provided are methods of treating a patient diagnosed with HCC and expressing a low level of miR-26, wherein treatment comprises IFN-α therapy.
摘要翻译：本文公开了相对于非癌组织，肝细胞（HCC）肿瘤组织中microRNA-26的表达降低，并且低水平的microRNA-26与不良临床结果相关。本文还公开了低表达水平的微小RNA-26与HCC患者中对干扰素（IFN）-α治疗的有利反应相关。因此，本文提供了一种预测诊断为HCC的患者的临床结果的方法，包括检测从患者获得的样品中的microRNA-26表达水平。还提供了选择被诊断为HCC的患者作为IFN-α治疗的候选者的方法，包括检测从患者获得的样品中的microRNA-26表达水平。还提供了鉴定用于治疗HCC的治疗剂的方法，其包括在体外筛选候选试剂以选择增加HCC细胞中微小RNA-26表达的试剂。还提供了治疗诊断为HCC并表达低水平的miR-26的患者的方法，其中治疗包括IFN-α治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式